Clinical Trial Results:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF)
Summary
|
|
EudraCT number |
2008-004405-34 |
Trial protocol |
CZ IE DE AT BE ES NL FR GB IT |
Global completion date |
28 Feb 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Feb 2016
|
First version publication date |
12 Feb 2016
|
Other versions |
|
Summary report(s) |
GS-US-231-0101 FDAAA Results Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.